TG13 antimicrobial therapy for acute cholangitis and cholecystitis

Harumi Gomi; Joseph S. Solomkin; Tadahiro Takada; Steven M. Strasberg; Henry A. Pitt; Masahiro Yoshida; Shinya Kusachi; Toshihiko Mayumi; Fumihiko Miura; Seiki Kiriyama; Masamichi Yokoe; Yasutoshi Kimura; Ryota Higuchi; John A. Windsor; Christos Dervenis; Kui Hin Liau; Myung Hwan Kim

doi:10.1007/s00534-012-0572-0

TG13 antimicrobial therapy for acute cholangitis and cholecystitis

Harumi Gomi, Joseph S. Solomkin, Tadahiro Takada, Steven M. Strasberg, Henry A. Pitt, Masahiro Yoshida, Shinya Kusachi, Toshihiko Mayumi, Fumihiko Miura, Seiki Kiriyama, Masamichi Yokoe, Yasutoshi Kimura, Ryota Higuchi, John A. Windsor, Christos Dervenis, Kui Hin Liau, Myung Hwan Kim

Research output: Contribution to journal › Article › peer-review

94 Scopus citations

Abstract

Therapy with appropriate antimicrobial agents is an important component in the management of patients with acute cholangitis and/or acute cholecystitis. In the updated Tokyo Guidelines (TG13), we recommend antimicrobial agents that are suitable from a global perspective for management of these infections. These recommendations focus primarily on empirical therapy (presumptive therapy), provided before the infecting isolates are identified. Such therapy depends upon knowledge of both local microbial epidemiology and patient-specific factors that affect selection of appropriate agents. These patient-specific factors include prior contact with the health care system, and we separate community-acquired versus healthcare-associated infections because of the higher risk of resistance in the latter. Selection of agents for community-acquired infections is also recommended on the basis of severity (grades I-III). Free full-text articles and a mobile application of TG13 are available via http://www.jshbps.jp/en/guideline/tg13.html.

Original language	English (US)
Pages (from-to)	60-70
Number of pages	11
Journal	Journal of Hepato-Biliary-Pancreatic Sciences
Volume	20
Issue number	1
DOIs	https://doi.org/10.1007/s00534-012-0572-0
State	Published - Jan 2013
Externally published	Yes

Keywords

Acute cholangitis
Acute cholecystitis
Antimicrobial therapy
Biliary tract infection
Treatment guidelines

ASJC Scopus subject areas

Surgery
Hepatology

Access to Document

10.1007/s00534-012-0572-0

Cite this

Gomi, H., Solomkin, J. S., Takada, T., Strasberg, S. M., Pitt, H. A., Yoshida, M., Kusachi, S., Mayumi, T., Miura, F., Kiriyama, S., Yokoe, M., Kimura, Y., Higuchi, R., Windsor, J. A., Dervenis, C., Liau, K. H., & Kim, M. H. (2013). TG13 antimicrobial therapy for acute cholangitis and cholecystitis. Journal of Hepato-Biliary-Pancreatic Sciences, 20(1), 60-70. https://doi.org/10.1007/s00534-012-0572-0

Gomi, H, Solomkin, JS, Takada, T, Strasberg, SM, Pitt, HA, Yoshida, M, Kusachi, S, Mayumi, T, Miura, F, Kiriyama, S, Yokoe, M, Kimura, Y, Higuchi, R, Windsor, JA, Dervenis, C, Liau, KH & Kim, MH 2013, 'TG13 antimicrobial therapy for acute cholangitis and cholecystitis', Journal of Hepato-Biliary-Pancreatic Sciences, vol. 20, no. 1, pp. 60-70. https://doi.org/10.1007/s00534-012-0572-0

@article{83336846e8cf4342a477a755db02313d,

title = "TG13 antimicrobial therapy for acute cholangitis and cholecystitis",

abstract = "Therapy with appropriate antimicrobial agents is an important component in the management of patients with acute cholangitis and/or acute cholecystitis. In the updated Tokyo Guidelines (TG13), we recommend antimicrobial agents that are suitable from a global perspective for management of these infections. These recommendations focus primarily on empirical therapy (presumptive therapy), provided before the infecting isolates are identified. Such therapy depends upon knowledge of both local microbial epidemiology and patient-specific factors that affect selection of appropriate agents. These patient-specific factors include prior contact with the health care system, and we separate community-acquired versus healthcare-associated infections because of the higher risk of resistance in the latter. Selection of agents for community-acquired infections is also recommended on the basis of severity (grades I-III). Free full-text articles and a mobile application of TG13 are available via http://www.jshbps.jp/en/guideline/tg13.html.",

keywords = "Acute cholangitis, Acute cholecystitis, Antimicrobial therapy, Biliary tract infection, Treatment guidelines",

author = "Harumi Gomi and Solomkin, {Joseph S.} and Tadahiro Takada and Strasberg, {Steven M.} and Pitt, {Henry A.} and Masahiro Yoshida and Shinya Kusachi and Toshihiko Mayumi and Fumihiko Miura and Seiki Kiriyama and Masamichi Yokoe and Yasutoshi Kimura and Ryota Higuchi and Windsor, {John A.} and Christos Dervenis and Liau, {Kui Hin} and Kim, {Myung Hwan}",

year = "2013",

month = jan,

doi = "10.1007/s00534-012-0572-0",

language = "English (US)",

volume = "20",

pages = "60--70",

journal = "Journal of Hepato-Biliary-Pancreatic Sciences",

issn = "1868-6974",

publisher = "Springer Verlag",

number = "1",

}

TY - JOUR

T1 - TG13 antimicrobial therapy for acute cholangitis and cholecystitis

AU - Gomi, Harumi

AU - Solomkin, Joseph S.

AU - Takada, Tadahiro

AU - Strasberg, Steven M.

AU - Pitt, Henry A.

AU - Yoshida, Masahiro

AU - Kusachi, Shinya

AU - Mayumi, Toshihiko

AU - Miura, Fumihiko

AU - Kiriyama, Seiki

AU - Yokoe, Masamichi

AU - Kimura, Yasutoshi

AU - Higuchi, Ryota

AU - Windsor, John A.

AU - Dervenis, Christos

AU - Liau, Kui Hin

AU - Kim, Myung Hwan

PY - 2013/1

Y1 - 2013/1

N2 - Therapy with appropriate antimicrobial agents is an important component in the management of patients with acute cholangitis and/or acute cholecystitis. In the updated Tokyo Guidelines (TG13), we recommend antimicrobial agents that are suitable from a global perspective for management of these infections. These recommendations focus primarily on empirical therapy (presumptive therapy), provided before the infecting isolates are identified. Such therapy depends upon knowledge of both local microbial epidemiology and patient-specific factors that affect selection of appropriate agents. These patient-specific factors include prior contact with the health care system, and we separate community-acquired versus healthcare-associated infections because of the higher risk of resistance in the latter. Selection of agents for community-acquired infections is also recommended on the basis of severity (grades I-III). Free full-text articles and a mobile application of TG13 are available via http://www.jshbps.jp/en/guideline/tg13.html.

AB - Therapy with appropriate antimicrobial agents is an important component in the management of patients with acute cholangitis and/or acute cholecystitis. In the updated Tokyo Guidelines (TG13), we recommend antimicrobial agents that are suitable from a global perspective for management of these infections. These recommendations focus primarily on empirical therapy (presumptive therapy), provided before the infecting isolates are identified. Such therapy depends upon knowledge of both local microbial epidemiology and patient-specific factors that affect selection of appropriate agents. These patient-specific factors include prior contact with the health care system, and we separate community-acquired versus healthcare-associated infections because of the higher risk of resistance in the latter. Selection of agents for community-acquired infections is also recommended on the basis of severity (grades I-III). Free full-text articles and a mobile application of TG13 are available via http://www.jshbps.jp/en/guideline/tg13.html.

KW - Acute cholangitis

KW - Acute cholecystitis

KW - Antimicrobial therapy

KW - Biliary tract infection

KW - Treatment guidelines

UR - http://www.scopus.com/inward/record.url?scp=84873439330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873439330&partnerID=8YFLogxK

U2 - 10.1007/s00534-012-0572-0

DO - 10.1007/s00534-012-0572-0

M3 - Article

C2 - 23340954

AN - SCOPUS:84873439330

SN - 1868-6974

VL - 20

SP - 60

EP - 70

JO - Journal of Hepato-Biliary-Pancreatic Sciences

JF - Journal of Hepato-Biliary-Pancreatic Sciences

IS - 1

ER -

TG13 antimicrobial therapy for acute cholangitis and cholecystitis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this